fluvoxamine / Generic mfg. - LARVOL DELTA

An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications. (PubMed, Expert Opin Drug Metab Toxicol) - "Some antidepressants, including fluoxetine, paroxetine, fluvoxamine, are moderate to strong inhibitors of various cytochrome P450 (CYP) isoenzymes and may cause clinically relevant interactions with ASMs metabolized by these pathways. First-generation ASMs with enzyme-inducing properties (e.g. carbamazepine, phenobarbital, and phenytoin) or enzyme-inhibiting effects (e.g. valproic acid) may alter the PK profile of several antidepressants, potentially leading to reduced therapeutic efficacy or dose-dependent toxicity...Antidepressants and ASMs are associated with a considerable risk of clinically significant DDIs. A thorough understanding of the underlying PK and PD mechanisms, combined with complementary strategies including therapeutic drug monitoring, consultation of interaction databases, and careful clinical monitoring, is essential to anticipate, prevent, and effectively manage adverse DDIs."

Journal • PK/PD data • Review • CNS Disorders • Epilepsy

Characterization of fluvoxamine degradation products in postmortem blood by liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry. (PubMed, Forensic Toxicol) - No abstract available

Journal

Precision dosing of clozapine: A physiologically based pharmacokinetic/pharmacodynamic model integrating genetic polymorphisms and clinical outcomes. (PubMed, J Psychopharmacol) - "This PBPK/PD model provides a robust framework for precision clozapine therapy, supporting genotype-guided dosing and TDM to optimize efficacy and safety. The implementation of pharmacogenetic testing could transform clinical practice, offering a framework for optimized resource utilization and risk minimization."

Clinical data • Journal • PK/PD data • Agranulocytosis • Cardiovascular • CNS Disorders • Epilepsy • Granulocytopenia • Pediatrics • Psychiatry • Schizophrenia • ABCB1 • CYP1A2 • GSTM1 • GSTT1

MD FluNCS: Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery (clinicaltrials.gov) - P3 | N=46 | Recruiting | Sponsor: Washington University School of Medicine | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • CNS Disorders

UHPLC-MS-Based Analysis of Fluvoxamine in Rabbit Aqueous Humour and Serum: Method Development and Validation. (PubMed, Pharmaceuticals (Basel)) - "Our method was proved to be linear in the 0.0625-1.5 µg/mL range and was validated according to the EMA guidelines. The simplicity of sample preparation, the tolerable matrix effects, and the favourable detection parameters provide a robust tool for preclinical pharmacokinetic and pharmacodynamic studies of FLU's ocular protective effects."

Journal • Preclinical • Glaucoma • Ophthalmology

Evaluating the Impact of CYP2D6 Phenotype on Fluvoxamine Pharmacokinetics in Geriatric Patients Using Physiologically Based Pharmacokinetic Modeling. (PubMed, Pharmaceutics) - "Based on these simulations, doses of approximately 50 mg/day for PMs, 50-100 mg/day for intermediate metabolizers (IMs), 100 mg/day for EMs, and 150-200 mg/day for ultrarapid metabolizers (UMs) may be appropriate for elderly patients, accompanied by cautious dose escalation and clinical monitoring. These findings suggest that CYP2D6 genotype-guided dosing may be a useful strategy for optimizing fluvoxamine therapy in elderly patients, with the potential to improve treatment outcomes while minimizing the risk of adverse drug reactions in this high-risk population."

Journal • PK/PD data • CNS Disorders • Depression • Geriatric Disorders • Mood Disorders • Psychiatry

Assessment of Off-Label Psychotropic Drug Use in Children and Adolescents: A Multi-Center Cross-Sectional Study in China. (PubMed, Pharmacoepidemiol Drug Saf) - "Off-label use of psychotropic drugs is highly prevalent in children and adolescents. The use of psychotropic drugs should be based on instructions and evidence-based medical evidence to ensure their rational use in these patient populations. The drug administration should standardize the practice of pediatric prescription in the future."

Journal • Observational data • Retrospective data • CNS Disorders • Mood Disorders • Pediatrics • Psychiatry

Current options for the treatment of anxiety in adults with autism spectrum disorder. (PubMed, Expert Rev Neurother) - "Pharmacological treatments show mixed fluvoxamine and clomipramine have shown promise, while citalopram, propranolol, and intranasal oxytocin yielded limited efficacy. Equity in care critical to improving access for this underserved population and requires comprehensive education in neurodevelopmental disorders for researchers and clinicians. Further research and innovation are needed to validate tools and optimize treatment strategies for this often-excluded population."

Journal • Review • Autism Spectrum Disorder • CNS Disorders • Critical care • Depression • Developmental Disorders • General Anxiety Disorder • Genetic Disorders • Mood Disorders • Psychiatry

Cardiac Valvular Incompetence Associated With Selective Serotonin Reuptake Inhibitors (SSRIs): A Disproportionality and Risk Factor Analysis From Global Safety Reports. (PubMed, Cureus) - "Methods In this study, we utilized VigiBase, the World Health Organization's global pharmacovigilance database, to examine potential safety signals related to cardiac valvular incompetence among users of six SSRIs: sertraline, paroxetine, fluoxetine, fluvoxamine, citalopram, and escitalopram. Adjusted logistic regression analysis identified pre-existing cardiac comorbidities and concomitant medications for which there is evidence of serotonin dysregulation and valvopathy as independent predictors of valvopathy. Prospective cohort studies, mechanistic research, and real-world evidence are essential to substantiate these pharmacovigilance signals and to elucidate potential pathophysiological mechanisms."

Journal • Cardiovascular • Heart Failure • HTR2B

OBSESSIVE-COMPULSIVE DISORDER: A CASE REPORT ABOUT CULTURAL AND RELIGIOUS BARRIERS TO TREATMENT (WRMC 2026) - "We report the case of a 31-year-old Hispanic man with no prior psychiatric history, though with a past psilocybin, methamphetamine, and cannabis use, who was referred for intrusive violent and sexual thoughts, including images of harming others...In Japan, he was prescribed Sulpiride 50 mg and Estazolam 2 mg once daily, with minimal relief...He was started on Clonazepam 1 mg nightly, Fluoxetine 40 mg daily, and Risperidone 0.5 mg twice daily...Fluvoxamine 50 mg daily was initiated but self-discontinued due to palpitations...A sensitive, multidisciplinary approach that respected the patient's worldview while maintaining therapeutic alliance proved essential for adherence and improvement. Awareness of these barriers may guide clinicians in tailoring interventions that address both psychiatric symptoms and the patient's cultural context."

Case report • Clinical • Depression • Mood Disorders • Obsessive-Compulsive Disorder • Suicidal Ideation

Male sexual dysfunction associated with selective serotonin reuptake inhibitors (SSRIs): A pharmacovigilance disproportionality analysis of FAERS data. (PubMed, J Affect Disord) - "This FAERS analysis detected significant disproportionality signals for male sexual dysfunction across SSRIs. Signal variation reflects reporting differences, not comparative risk, due to database limitations. These findings highlight the need for clinical vigilance and further investigation."

Adverse events • Journal • CNS Disorders • Depression • Erectile Dysfunction • Psychiatry • Sexual Disorders

Temporal Patterns of Adverse Events Associated With Selective Serotonin Reuptake Inhibitors: A Global Pharmacovigilance Analysis of Early-Onset Versus Late-Onset Toxicity. (PubMed, Cureus) - "Objective This study aims to explore the timing of AEs associated with six commonly used SSRIs: sertraline, fluoxetine, fluvoxamine, paroxetine, citalopram, and escitalopram using global pharmacovigilance data, with a focus on early- versus late-onset profiles. Early-onset symptoms require timely management to improve tolerability, while late-onset effects highlight the need for ongoing monitoring. These findings can inform personalized monitoring strategies and guide patient counseling to support safer long-term SSRI use."

Adverse events • Journal • CNS Disorders • Dermatology • Diabetes • Insomnia • Metabolic Disorders • Osteoporosis • Rheumatology • Sexual Disorders • Sleep Disorder

Multidisciplinary diagnosis and treatment of iatrogenic Cushing syndrome in a patient with obsessive-compulsive disorder. (PubMed, Endocrinol Diabetes Metab Case Rep) - "After the appearance of oral ulcers, the patient uncontrollably used a large amount of chlorhexidine dexamethasone membranes, resulting in iatrogenic Cushing syndrome. The fatty liver and abnormal liver function associated with Cushing syndrome led to the discontinuation of fluvoxamine and aripiprazole for obsessive-compulsive disorder...Multidisciplinary diagnosis and treatment in general hospitals are advantageous or even the only option for improving the prognosis of comorbid mental disorders and somatic diseases. Consultation liaison with psychiatry should be strengthened in general hospitals, especially in the diagnosis and treatment of diseases that are often complicated with psychological symptoms, such as in the endocrinology department."

Journal • CNS Disorders • Cushing’s Disease • Endocrine Disorders • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • Tic Disorders • Tourette Syndrome

Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations. (PubMed, Pharmacoecon Open) - "Cost effectiveness varied widely across studies due to differences in variant periods, population risk profiles, model assumptions, and healthcare systems. Future research should integrate variant-specific effectiveness, real-world vaccine responsiveness, long-term COVID-19 outcomes, and adverse events to better inform resource allocation for transplant and other high-risk populations."

HEOR • Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation

RTMS Versus Fluvoxamine in the Treatment of OCD: A Randomized Open-label Pilot Study. (PubMed, Int J Med Sci) - " This trial revealed that low-frequency repetitive transcranial magnetic stimulation over the supplementary motor area might have preliminary positive outcomes for treatment-naïve patients with obsessive‒compulsive disorder. Our findings can be considered a good signal to promote further research in the form of randomized, double-blind, sham-controlled multicenter trials with extended follow-up periods."

Clinical • Journal • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

ESPRIT: sElective Serotonin reuPtake inhibitoRs In posT-covid (clinicaltrials.gov) - P3 | N=160 | Not yet recruiting | Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

New P3 trial • Infectious Disease • Novel Coronavirus Disease

Lurasidone and Fluvoxamine Combination in Eating Disorders with Comorbid Obsessive-Compulsive Disorder: Preliminary Evidence from an Observational Study. (PubMed, Med Sci (Basel)) - "Within the constraints of this small, all-female inpatient cohort, the findings illustrate directional, time-related changes compatible with global rehabilitation effects rather than drug-specific efficacy. The study demonstrates the feasibility-and methodological challenges-of applying Bayesian longitudinal modeling to incomplete clinical datasets. Future randomized or adaptive trials incorporating objective endpoints and data-quality pipelines are warranted to test whether serotonergic-dopaminergic-σ-1 synergy provides genuine clinical benefit in the AN-OCD spectrum."

Journal • Observational data • Anorexia • CNS Disorders • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry

Not Available (PubMed, Psychiatry Clin Psychopharmacol) - "In 2024, she received four 56 mg doses of Spravato over 2 weeks while maintaining duloxetine, fluvoxamine, and clozapine therapy. No severe adverse events (dissociation, psychosis, or hypertensive crises) were observed. Although limited by an abbreviated treatment regimen and a single-case design, this case suggests that esketamine may be considered in carefully selected TRD patients with structural brain abnormalities and prior ECT poor response, pending validation from larger studies."

Journal • CNS Disorders • Depression • Psychiatry • Suicidal Ideation • Vascular Neurology

Prolonged Tardive Dyskinesia Induced by Long-Acting Paliperidone Palmitate in Schizophrenia: A Case Report. (PubMed, Am J Case Rep) - "Dose reduction to 350 mg was ineffective; the long-acting injection was stopped in June 2019, and aripiprazole 10 mg/day was started. Adjuncts (trihexyphenidyl, amantadine, and intermittent benzodiazepines) provided only limited benefit...Over 6 years without vesicular monoamine transporter 2 (VMAT-2) inhibitors, her dystonia lessened but persisted, and she was discharged on clozapine and fluvoxamine...Given therapeutic limits, variable prognosis, and the 3-month formulation's extended pharmacokinetics, clinicians should maintain high suspicion, minimize dopamine-receptor-blocking exposure, and individualize care, considering timely VMAT-2 inhibitors or clozapine, plus structured long-term motor monitoring and shared decision-making. This report highlights the presentation of tardive dyskinesia as a complication of antipsychotic medication and the approach to management of this iatrogenic syndrome."

Journal • CNS Disorders • Dystonia • Movement Disorders • Psychiatry • Schizophrenia

Comparative Real-World Safety Profiles of Six Selective Serotonin Reuptake Inhibitors: A Global Pharmacovigilance Analysis. (PubMed, Cureus) - "Methods We conducted a comprehensive pharmacovigilance analysis utilizing VigiBase, the WHO global database of individual case safety reports, encompassing over 342,000 reports for six major SSRIs (sertraline, fluoxetine, paroxetine, citalopram, escitalopram, and fluvoxamine). Conclusions This analysis reveals that SSRIs exhibit distinct safety profiles that correlate with their pharmacodynamic properties, challenging the traditional view of these medications as a homogeneous therapeutic class. These findings support precision prescribing approaches based on individual patient risk factors and provide mechanistic insights for evidence-based SSRI selection."

Adverse events • Journal • Real-world evidence • CNS Disorders • Sexual Disorders • Sleep Disorder

Middle meningeal artery lidocaine infusion for refractory migraine: First case report in Portugal (EHF-EHC 2025) - "Various pharmacologic classes were tried without benefit: antihypertensives and calcium channel blockers (propranolol, candesartan, flunarizine), antiepileptics (valproic acid, topiramate, oxcarbazepine), antidepressants (amitriptyline, nortriptyline, venlafaxine, fluvoxamine, sertraline, clomipramine), other preventives (prednisolone, oxitriptan, melatonin), cycles of botulinum toxin (PREEMPT protocol), monoclonal antibodies (galcanezumab, fremanezumab, erenumab), and atogepant. At the time of the procedure, the patient was on eptinezumab 100 mg and botulinum toxin every three months but continued to have daily headaches, with severe intensity and reliance on eletriptan for acute relief... MMA lidocaine infusion has been described in few cases, and this is, to our knowledge, the first reported in Portugal. It constitutes an invasive therapeutic approach that should be considered only as a rescue option for carefully selected patients with severely refractory migraine...."

Case report • Clinical • Anorexia • CNS Disorders • Migraine • Pain

Risk of gastrointestinal bleeding by specific SSRIs and SNRIs: A systematic review and meta-analysis. (PubMed, Br J Clin Pharmacol) - "GIB is an uncommon adverse event, but this analysis demonstrates that the risk of GIB is elevated for commonly used SSRI/SNRI products, highlighting the relevance for those patients with an increased risk of GIB."

Journal • Retrospective data • Review • Gastroenterology

Neuroinflammation as a therapeutic target in post-stroke depression (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "A promising direction is the use of antidepressants with a multimodal mechanism of action, such as the original drug fluvoxamine, which combines serotonergic effects with anti-inflammatory and neuroprotective properties via sigma-1 (σ1) receptor agonism. Optimizing PSD treatment is achievable through the implementation of a personalized approach, including long-term screening and comprehensive management of the identified disorders."

Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Depression • Inflammation • Mood Disorders • Psychiatry • BDNF

MD FluNCS: Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery (clinicaltrials.gov) - P3 | N=46 | Not yet recruiting | Sponsor: Washington University School of Medicine | Initiation date: Oct 2025 ➔ Feb 2026

Trial initiation date • Cardiovascular • CNS Disorders

Fluvoxamine for Long COVID-19 (clinicaltrials.gov) - P2/3 | N=191 | Completed | Sponsor: Washington University School of Medicine | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease